59907-36-7

Upstream product

• 104-01-8 4-Methoxyphenylacetic acid 
• 96-31-1 N,N'-Dimethylurea 
• 74-89-5 methylamine 
• 1608-24-8 3-(2,2-difluoroethenyl)anisole 
• 23786-14-3 4-methoxy-phenyl acetic acid methyl ester 
• 4693-91-8 4-methoxyphenyl-acetic chloride 

Downstream Products

• 1267492-11-4 2-cyano-N-(4-methoxyphenethyl)-N-methylacetamide 
• 1431791-45-5 2-cyano-2-diazo-N-(4-methoxyphenethyl)-N-methylacetamide 
• 1041478-84-5 3-hydroxy-4-(4-methoxyphenyl)-1-methyl-1H-pyrrole-2,5-dione 
• 4091-50-3 N-methylhomoanisylamine 

Relevant academic research and scientific papers

Direct synthesis of amides from nonactivated carboxylic acids using urea as nitrogen source and Mg(NO3)2or imidazole as catalysts

A new method for the direct synthesis of primary and secondary amides from carboxylic acids is described using Mg(NO3)2·6H2O or imidazole as a low-cost and readily available catalyst, and urea as a stable, and easy to manipulate nitrogen source. This methodology is particularly useful for the direct synthesis of primary and methyl amides avoiding the use of ammonia and methylamine gas which can be tedious to manipulate. Furthermore, the transformation does not require the employment of coupling or activating agents which are commonly required.

Rh(III)-Catalyzed Distal C-H Alkenylation of Weakly Coordinating Acetamides Via Desilylation Pathway

Rh(III)-Catalyzed distal ortho-C?H alkenylation of arylacetamides have been reported employing acetamide, a weak coordinating group, as a directing group. This challenging C?H alkenylation of arylacetamides has been achieved by using arylalkynyl silanes as a surrogate for terminal alkynes under redox neutral process through desilylation pathway. The control experiments suggest that the in situ generatedRh-species is likely to be Lewis acidic, which is playing a vital role in the desilylation step. (Figure presented.).

Direct defluorinative amidation-hydrolysis reaction of gem-difluoroalkenes with N,N-dimethylformamide, and primary and secondary amines

A novel and efficient method for the synthesis of arylacetamides by the reactions of gem-difluoroalkenes with N,N-dialkylformamides, and primary and secondary amines with the assistance of KOtBu and water was developed.

Synthesis of aryl anilinomaleimide based derivatives as glycogen synthase kinase-3β inhibitors with potential role as antidepressant agents

A series of aryl anilinomaleimide based derivatives has been synthesized and evaluated for in vitro glycogen synthase kinase-3β (GSK-3β) inhibitory activity. A large number of compounds from the series exhibited moderate to potent inhibitory activity against GSK-3β, with more than one-third of the compounds showing inhibition with IC50 values 50 values of 0.09, 0.12, 0.17, 0.19, 0.21 and 0.23 μM respectively), were further investigated for antidepressant activity by the widely accepted forced swim test and tail suspension test (FST and TST) models. All the tested compounds displayed antidepressant-like effects, particularly compounds 8j and 8b, which exhibited significant antidepressant activity, about 1.4-fold higher than fluoxetine, a standard antidepressant drug in both FST and TST. Preliminary structure-activity relationships have also been generated based on the experimental data obtained.

α-Diazo-β-ketonitriles: Uniquely reactive substrates for arene and alkene cyclopropanation

An investigation of the intramolecular cyclopropanation reactions of α-diazo-β-ketonitriles is reported. These studies reveal that α-diazo-β-ketonitriles exhibit unique reactivity in their ability to undergo arene cyclopropanation reactions; other similar acceptor-acceptor- substituted diazo substrates instead produce mixtures of C-H insertion and dimerization products. α-Diazo-β-ketonitriles also undergo highly efficient intramolecular cyclopropanation of tri- and tetrasubstituted alkenes. In addition, the α-cyano-α-ketocyclopropane products are demonstrated to serve as substrates for SN2, SN2′, and aldehyde cycloaddition reactions.

THIENOPYRIDINE-PHENYLACET AMIDES AND THEIR DERIVATIVES USEFUL AS NEW ANTI-ANGIOGENIC AGENTS

The invention relates to compounds represented by Formula (I):, and to prodrugs thereof, pharmaceutically salts or solvates of said compounds or said prodrugs, wherein each of X1-X5 and R1-R5 are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).